Treatment of Overactive Bladder With Anticholinergic Agents

N/AActive Not RecruitingNCT07046156

Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital120 enrolled

Overview

This study aims to evaluate the efficacy and adverse effect incidence of three different anticholinergics (oxybutinin, propiverine, and tolterodine) that are used in children with overactive bladder.

A total of approximately 150 patients with overactive bladder will be evaluated retrospectively. Clinical and demographic data and voiding diaries of these patients will be evaluated. For this purpose, patients will be divided into mainly three groups according to the anticholinergic agent used.

Study Type

OBSERVATIONAL

Enrollment

120

Conditions

Overactive Bladder

Interventions

Oxybutynin ClDRUG

Oxybutynin in a dose of 0.5 mg/kg will be used in the treatment of overactive bladder

propiverineDRUG

Propiverine in a dose of 0.8 mg/kg will be used in the treatment of overactive bladder

TolterodineDRUG

Tolterodine in a dose of 0.1 mg/kg will be used in the treatment of overactive bladder

Eligibility

Sex: ALLMin age: 5 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed with overactive bladder * Patients treated with an anticholinergic Exclusion Criteria: * Presence of anatomical or neurological problems * Patients with missing data

Locations (1)

Sancaktepe Sehit Prof dr Ilhan Varank Training and Research Hospital

Istanbul, Turkey (Türkiye)

Outcomes

Primary Outcomes

Number of patients treated with anticholinergic

Time frame: 6 months

Number of patients with drug related adverse effects

Time frame: 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.